Allena Pharmaceuticals Inc. (NASDAQ: ALNA) Attends 31st Annual ROTH Conference
Allena Pharmaceuticals (NASDAQ: ALNA) is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. For more information, visit the company's website at www.allenapharma.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of…







